`
`
`
`
`
`
`
`
`
`
`
` Paper No. ____
`
`Filed: May 26, 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
`INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS
`INC., and MYLAN INC.,
`Petitioner
`v.
`
`
`
`
`
`
`
`
`
`
`
` SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.,
`Patent Owner
`_________________
`Case IPR2015-00902
`U.S. Patent 8,669,290
`_________________
`
`PATENT OWNER’S UPDATED EXHIBIT LIST
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2015-00902
`U.S. Patent 8,669,290
`Further to 37 C.F.R. § 42.63(e), Patent Owner Senju Pharmaceutical Co.,
`
`Ltd., hereby submits a current listing of Senju Exhibits to counsel for Petitioner
`
`InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc.,
`
`InnoPharma LLC, Mylan Pharmaceuticals Inc., and Mylan Inc.
`
`Exhibit 2006
`
`Description
`Exhibits
`Exhibit 2001 Transcript of Teleconference with the Board, dated April 15, 2015.
`Exhibit 2002 U.S. Patent No. 8,669,290 to Sawa et al., “Aqueous Liquid
`Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic
`acid.”
`Exhibit 2003 U.S. Patent No. 8,754,131 to Sawa et al., “Aqueous Liquid
`Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic
`acid.”
`Exhibit 2004 U.S. Patent No. 8,871,813 to Sawa et al., “Aqueous Liquid
`Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic
`acid.”
`Exhibit 2005 U.S. Patent No. 8,927,606 to Sawa et al., “Aqueous Liquid
`Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic
`acid.”
`InnoPharma’s Paragraph IV Notice Letter dated September 19,
`2014.
`InnoPharma’s Paragraph IV Notice Letter dated October 30, 2014.
`Exhibit 2007
`InnoPharma’s Paragraph IV Notice Letter dated March 27, 2015.
`Exhibit 2008
`Exhibit 2009 Complaint, Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing,
`Inc. et al., No. 14-cv-06893 (D.N.J. Nov. 3, 2014), ECF No. 1.
`Exhibit 2010 Complaint, Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing,
`Inc. et al., No. 15-cv-03240 (D.N.J. May 8, 2015), ECF No. 1.
`Exhibit 2011 Consolidated scheduling order, Senju Pharm. Co., Ltd. et al. v.
`InnoPharma Licensing, Inc. et al., No. 14-cv-06893 (D.N.J. April
`16, 2015), ECF No. 30.
`Exhibit 2012 Amended scheduling order, Senju Pharm. Co., Ltd. et al. v. Lupin,
`Ltd. et al., No. 14-cv-00667 (D.N.J. Feb. 27, 2015), ECF No. 63.
`Exhibit 2013 Prolensa® (bromfenac ophthalmic solution 0.07%) Prescribing
`Information.
`
`
`
`2
`
`
`
`Case IPR2015-00902
`U.S. Patent 8,669,290
`Exhibit 2014 U.S. Patent No. 5,630,793 to Rowe, “Aqueous Ophthalmic
`Sprays.”
`Exhibit 2015 Press Release by Bausch + Lomb, dated April 8, 2013, entitled
`“Bausch + Lomb Receives FDA Approval for Prolensa™
`(bromfenac ophthalmic solution) 0.07%.”
`Exhibit 2016 Lupin’s Paragraph IV Notice Letter dated May 13, 2014.
`Exhibit 2017 Metrics’ Paragraph IV Notice Letter dated June 26, 2014.
`Exhibit 2018 Paddock’s Paragraph IV Notice Letter dated December 15, 2014.
`Exhibit 2019 Apotex’s Paragraph IV Notice Letter dated December 10, 2014.
`Exhibit 2020 Masson et al., Stabilisation of ionic drugs through complexation
`with non-ionic and ionic cyclodextrins, 164 INT’L J.
`PHARMACEUTICS 45 (1998).
`Exhibit 2021 Loftsson et al., Pharmaceutical Applications of Cyclodextrins, 85
`J. PHARMACEUTICAL SCIENCES 1017 (1996).
`Exhibit 2022 HSBC Global Research Lupin Company Report, Feb. 3, 2014,
`http://www.lupin.com/pdf/14/20140203%20-
`%20Lupin%203QFY14%20-%20HSBC.pdf
`Exhibit 2023 APOTEX ALL PRODUCTS,
`https://www.apotex.com/us/en/products/search.asp?qt=All&qs=&t
`=All%20Products.
`Exhibit 2024 Consent judgment, Senju Pharm. Co., Ltd. et al. v. Apotex Inc. et
`al., No. 15-cv-00336 (D.N.J. May 18, 2015), ECF No. 26.
`Exhibit 2025 U.S. Patent No. 5,856,345 to Doi et al., “Method for Stabilizing
`Pranoprofen and Stable Liquid Preparation of Pranoprofen.”
`Exhibit 2026 Xibrom® Prescribing Information.
`Exhibit 2027 Bromday® Prescribing Information.
`Exhibit 2028 Drugs@FDA, Listing of FDA-approved bromfenac ophthalmic
`solution 0.09% products,
`http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?f
`useaction=Search.Overview&DrugName=BROMFENAC%20SO
`DIUM.
`Exhibit 2029 Sheryl Gay Stolberg, New Painkiller is Withdrawn After 4 Deaths,
`N.Y. TIMES, Jun. 23, 1998.
`Exhibit 2030 Baklayan et al., The ocular distribution of 14C-labeled bromfenac
`ophthalmic solution 0.07% in a rabbit model, CLINICAL 2014:8
`OPHTHALMOLOGY 1717 (2014).
`
`
`
`3
`
`
`
`
`
`
`
`Dated: May 26, 2015
`
`Case IPR2015-00902
`U.S. Patent 8,669,290
`
`Respectfully submitted,
`
`By: /Bryan C. Diner/
`Bryan C. Diner, Lead Counsel
`Reg. No. 32,409
`
`Counsel for Patent Owner
`
`
`
`
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2015-00902
`U.S. Patent 8,669,290
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Updated Exhibit List and Exhibits 2002 - 2030 were served on May
`
`26, 2015, via email directed to counsel of record for the Petitioner at the following:
`
`Jitendra Malik
`jitty.malik@alston.com
`
`Bryan Skelton
`bryan.skelton@alston.com
`
`Lance Soderstrom
`lance.soderstrom@alston.com
`
`
`
`Date: May 26, 2015
`
`/Ashley F. Cheung/
`Ashley F. Cheung
`Case Manager
`
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, LLP
`
`
`
`
`
`
`5
`
`
`
`
`
`
`
`